Compare NICE Ltd (NICE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Viatris Inc — how do they compare? NICE Ltd trades at $94.34 (market cap $5.91B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 3.3× NICE Ltd's market cap, and Viatris Inc pays a 2.83% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| NICE | VTRS | |
|---|---|---|
Market Cap | $5.91B | $19.79B |
Sector | Technology | Health |
52-Week High | $170.37 | $17.39 |
52-Week Low | $83.15 | $8.74 |
Enterprise Value | $5.69B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE trades at $101.34, up 1.19% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 17.57% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights AI-driven customer engagement expansions, including a partnership with Banco do Brasil announced on July 14, 2026.
The outlook is positive with a consensus price target of $124.88, implying significant upside. Risks include a projected decline in net income for 2026 and competitive pressures in the technology sector. The absence of sell ratings from analysts underscores underlying strength, but investors should monitor execution against future earnings expectations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
